No Adverse Side Effects Of Covid-19 Vaccine: Study

Hyderabad : Vaccines administered in the city so far for prevention of Covid-19 did not show any major adverse reaction. All the side-effects reported after Covid-19 vaccination are in terms of the manufacturer’s data and the doses administered are safe, says a research study conducted by a city-based medical college and hospital.

Most of the people, who reported minor side-effects after vaccination, are in the age group of 18 to 28 years. Pain in injection site was reported in 45 per cent and fever in 31 per cent of the vaccinated population. But all side-effects were normal and subsided soon afterwards, the study revealed.

“The overall results found the occurrence of side-effects are in the terms of the manufacturer’s data and it has been noticed in young age. The presence of local side-effects should not hamper the vaccination drive to protect against the pandemic. This study imparts the confidence for taking vaccination and further studies are required to strengthen the will of public to boost confidence to take vaccine in the present vaccination drive,” said the researchers from the Kamineni Academy of Medical Sciences and Research Centre, Hyderabad.

The research team comprised Sunil Pal Singh Chajhlana, Anjaiah Kanusali, Guru Prasad Manderwad, Vineesh Allenki and Shashidhar Kamineni. The results of the research study were published in the latest issue of the science journal, International Journal of Community Medicine and Public Health. The research team studied Covishield vaccine.

The cross-sectional study was conducted between January 2021 and February 2021 among healthcare workers vaccinated using a validated questionnaire. Study subjects were contacted to know about any adverse events following immunization for 0-24 hours, 24-48 hours and 48-72 hours.

“As many as 1,364 healthcare workers participated in the study. Majority of the symptoms following immunization were highest in age group of 18-28 years. Reported symptoms were pain at the site of injection in 45.4%, fever in 31%, body pains in 23.3%, headache in 13.9%, tiredness in 10.4%, swelling at the site of injection in 2.9%, dizziness in 2.2%, redness at the site of injection in 1.8%, joint pains in 1.7%, rash in 0.4%, breathlessness in 0.2%,” the study said.

The study found that in the next 24-48 hours after vaccination, there was a major decline in the symptoms reported compared to the symptoms reported in the first 24 hours after vaccination. “The symptoms in the vaccination population a day after the jab were pain at the site of injection 5.7%, fever 2.8%, body pains 2.8%, headache 2.3%, and tiredness 1.8%. In the 48-72 hours post vaccination, almost all the symptoms reported showed decreasing trends like pain 4.2%, fever 2.1%, body pains 1.9%, headache 1.1% and tiredness 1.3% in comparison with the previous two days. There were no cases reported with joint pains, rash and breathlessness on the third day”, the study added.

  • Related Posts

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    With heroin availability falling, Punjab Police claims the pattern of drug consumption and supply is changing. Pharmaceutical narcotics have now emerged as the state’s biggest drug enforcement challenge. Chandigarh: The…

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    Bengaluru: In a major breakthrough in the illegal pharmaceutical network operating in Karnataka, investigators from the Special Investigation Team (SIT) raided Krupa Health Care at Minerva Circle, seizing a cache…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit